Last €3.51 EUR
Change Today -0.061 / -1.71%
Volume 0.0
IM3 On Other Exchanges
As of 1:34 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

immunomedics inc (IM3) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - €4.49
52 Week Low
05/9/14 - €2.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUNOMEDICS INC (IM3)

immunomedics inc (IM3) Related Bloomberg News

View More Bloomberg News

immunomedics inc (IM3) Related Businessweek News

No Related Businessweek News Found

immunomedics inc (IM3) Details

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer. The company’s antibody-drug conjugate (ADC) products comprise IMMU-132, an ADC that contains SN-38, which is in Phase 2 clinical development focusing on triple-negative breast cancer and colorectal cancer; and IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II clinical development for the treatment of metastatic colorectal cancer. Its early-stage products include Veltuzumab, a humanized monoclonal antibody, which is in Phase 2 study; Milatuzumab, an anti-CD74 antibody for the treatment of graft-versus-host disease that has completed initial Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL, which is in Phase 1/2 clinical trial; Milatuzumab-Doxorubicin, a clinically-evaluated agent that is in Phase 1 dose-escalation trial; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone in patients. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has strategic partnership with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

120 Employees
Last Reported Date: 08/25/14
Founded in 1982

immunomedics inc (IM3) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $618.9K
Founder, Chairman of the Board, Chief Medical...
Total Annual Compensation: $584.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $235.5K
Total Annual Compensation: $56.6K
Compensation as of Fiscal Year 2014.

immunomedics inc (IM3) Key Developments

Immunomedics Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 08:00 AM

Immunomedics Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 08:00 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States.

Immunomedics, Inc. Presents Clinical Data on Novel Antibody-Drug Conjugates for Solid Cancer Therapy

Immunomedics Inc. announced Challenging the Dogmas: Clinical Efficacy of SN-38-Conjugated Antibodies in Solid Tumors, at the joint symposium of the European Organization for the Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI), and the American Association for Cancer Research (AACR). In his lecture, Dr. Goldenberg differentiated the company's antibody-drug conjugate (ADC) platform technology from other technologies. Dr. Goldenberg described Immunomedics ADC technology, which uses a moderately-toxic drug, SN-38 (the active metabolite of the prodrug, irinotecan), conjugated to either anti-TROP-2 (IMMU-132) or anti-CEACAM5 (IMMU-130) antibodies, at a drug to antibody ratio (DAR) of 7.6, which is about twice that of other ADCs. The company's patented conjugation chemistry achieved the high DAR by site-specifically attaching SN-38 to the antibody's interchain sulfhydryl groups without affecting the antibody's binding to the tumor, and in a manner that preserves the drug's activity while bound.

Immunomedics Inc. Reports Consolidated Earnings Results for the First Quarter Ended September 30, 2014

Immunomedics Inc. reported consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company reported total revenues were $1.1 million as compared to total revenues of $5.5 million for the same quarter last fiscal year. The decrease of $4.4 million in total Revenue was primarily due to a $4.6 million in license fee revenue earned upon fulfilling the company's obligations under the Algeta ASA service agreement, as amended, in the previous year. Operating loss was $12,444,134 against $5,233,345 a year ago. Loss before income tax expense was $12,430,799 against $5,221,682 a year ago. Net loss attributable to stockholders was $12.4 million, or $0.13 per share, compared with a net loss attributable to stockholders of $5.2 million, or $0.06 per share, for the same quarter in last year. The $7.2 million increase in net loss this quarter was primarily due to increased legal and professional fees, and higher research and development costs related to clinical trials in the current period, as well as higher net revenue related to the Algeta agreement in the prior period.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM3:GR €3.51 EUR -0.061

IM3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IM3.
View Industry Companies

Industry Analysis


Industry Average

Valuation IM3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 89.8x
Price/Book 15.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 83.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at